ARIAD to Webcast Conference Call on Third Quarter 2009 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Thursday, November 5, 2009. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company’s financial results for the nine months ended September 30, 2009, progress toward 2009 key corporate objectives and additional corporate activities.

The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. The call can be accessed by dialing 866-783-2146 (domestic) or 857-350-1605 (international) five minutes prior to the start time and providing the passcode 97543712. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks.

About ARIAD

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.